People: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.60USD
29 Dec 2014
Price Change (% chg)

$0.01 (+1.05%)
Prev Close
$0.59
Open
$0.57
Day's High
$0.60
Day's Low
$0.57
Volume
218,468
Avg. Vol
1,996,557
52-wk High
$1.62
52-wk Low
$0.48

Search Stocks

Dinges, Jude 

Brief Biography

Mr. Jude Dinges is the Chief Commercial Officer, Senior Vice President of Aeterna Zentaris Inc. He began his career nearly 30 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, sales, management, marketing, and market development. While at Merck, Mr. Dinges won multiple awards, including the President's Achievement Award in 2001, awarded to one of 32 Business Directors each year. He received the Change Agent Award for his market development prelaunch business planning and contributions to sales force execution, while launching the blockbuster brands Cozaar®, Fosamax®, Singulair®, Maxalt®, Vioxx®, and Vytorin®. He was recognized with a Career Achievement Award for his consistent top performance as a Senior/ Executive Business Director. Mr. Dinges joined Novartis Pharmaceuticals in 2006 and led his region to top performance in the launch of Tekturna® while balancing a broad antihypertensive portfolio across several Novartis divisions. His region also led the nation in market share for Exelon® and Exelon Patch®. In 2008, Mr. Dinges became the Respiratory & Infectious Disease Specialty Medicines Director. In 2009, Mr. Dinges joined Amgen Inc. as Executive Director of Region Sales, Bone Health Business Unit. Mr. Dinges led his region team to a highly successful launch of monoclonal antibody, Prolia®, across southeastern United States and Puerto Rico.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
121,988 -- 137,896 259,884

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Dodd

1,279,000

Dennis Turpin

403,092

Richard Sachse

--

Jude Dinges

259,884

Philip Theodore

--

Amelie Metivier

--
As Of 30 Dec 2013
Search Stocks